^
    Back
    Association details:
    Biomarker:EGFR I744_K745insKIPVAI
    Cancer:Lung Adenocarcinoma
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

    Excerpt:
    The del I744_K745insKIPVAI mutation was found in a 36-year-old former female smoker, with an adenocarcinoma of the lung….she received erlotinib at a 150 mg daily dose. A clinical meaningful improvement of symptoms was obtained within a few days, and a tumor assessment after 8 weeks showed a PR.
    DOI:
    10.1097/JTO.0b013e318227e8c6